Correction to: CCN2 inhibits lung cancer metastasis through promoting DAPK-dependent anoikis and inducing EGFR degradation

Cc, Chang; Mh, Yang; Lin, B-R; St, Chen; Pan, Szu-Hua; Hsiao, Michael; Tc, Lai; Lin, SK; Jeng, Yung‐Ming; Chu, Chia-Yu; Rh, Chen; Yang, Ping; Chin, Y. Eugene; Kuo, M-L

doi:10.1038/s41418-018-0140-5

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been more than 20 years since CTGF was first found to play a role in human cancer [29,30]. To date, CTGF expression has been found to be associated with various tumor types, including HCC [31], pancreatic cancer [32], lung cancer [33], and prostate cancer [34]. The role that CTGF plays in digestive system cancers is diverse and tumor specific (Figure 5).…”

Section: Discussionmentioning

confidence: 99%

Connective Tissue Growth Factor in Digestive System Cancers: A Review and Meta-Analysis

Zhao

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Aim. A meta-analysis was conducted to estimate the impact of connective tissue growth factor (CTGF) on outcomes in patients with digestive system cancers. Methods. A systemic literature survey was performed by searching the Cochrane Library and PubMed databases for articles that evaluated the impact of CTGF on outcomes in patients with digestive system cancers. Hazard ratios and 95% confidence intervals were calculated for prognostic factors, overall and recurrence-free survival using RevMan 5.3 software. Results. This meta-analysis was conducted to evaluate a total of 11 studies that included 1730 patients. The results showed that elevated CTGF expression was significantly correlated with advanced age, larger tumor size, multiple tumors, and vascular invasion. Subgroup analysis by cancer type revealed increased risk for lymph node metastasis and advanced tumor node metastasis (TNM) stage in gastric cancer, compared with colorectal cancer. An unfavorable effect of elevated CTGF levels on overall survival was found in patients with hepatocellular carcinoma and patients with gastric cancer, while survival was improved in colorectal cancer patients with high CTGF expression, compared to those with normal levels of CTGF. Conclusions. Elevated CTGF expression may be a novel biomarker for disease status and predicted survival outcomes in patients with specific digestive system cancers.

show abstract